Advanced Melanoma Clinical Trial Pipeline Expands as 55+ Pharma Companies Drive Innovation in Therapeutics, Finds DelveInsight | Pfizer, BioNTech SE, Genmab, Hanmi Pharmaceutical, Replimune

DelveInsight's "Advanced Melanoma - Pipeline Insight, 2026" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in the Advanced Melanoma pipeline landscape. It covers the Advanced Melanoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Advanced Melanoma treatment landscape. Learn more about the evolving Advanced Melanoma pipeline today @ https://www.delveinsight.com/sample-request/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Advanced Melanoma Pipeline Report

• In March 2026, Hanmi Pharmaceutical initiated a phase 2 study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations.
• In March 2026, Genmab initiated a clinical trial to evaluate the effectiveness and safety of the bispecific antibody acasunlimab alone or with pembrolizumab in participants with advanced melanoma.
• In March 2026, Suzhou BlueHorse Therapeutics announced that its phase II trial for advanced melanoma will follow up subjects for up to 24 months after treatment.
• In March 2026, Pfizer conducted a study to compare the efficacy and safety of encorafenib and binimetinib plus pembrolizumab versus placebo plus pembrolizumab.
• In October 2025, findings from the RELATIVITY-047 trial demonstrated that the combination of nivolumab and relatlimab achieved superior progression-free survival compared to nivolumab alone.
• The US FDA approved lifileucel (AMTAGVI) in 2024 as the first cellular therapy for a solid cancer, specifically for use in patients with advanced melanoma.
• DelveInsight's report highlights a robust clinical development space with 150+ key companies and 180+ pipeline drugs across the broader melanoma landscape.
• Leading Advanced Melanoma companies include Pfizer, BioNTech SE, Genmab, Hanmi Pharmaceutical, Replimune, Perspective Therapeutics, IO Biotech, and Amgen.
• Promising therapies in development include BNT111, VMT01, IO-102-IO-103, RP1, and several other candidates spanning monoclonal antibodies, small molecules, and gene therapies.

Download for updates and the latest revolution in Advanced Melanoma care @ https://www.delveinsight.com/sample-request/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Advanced Melanoma Emerging Drugs Profile

• BNT111: BioNTech SE
BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens. It is designed to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory or relapsed, unresectable Stage III or IV melanoma. By leveraging mRNA technology, it aims to stimulate the body's own immune system to recognize and destroy cancer cells. Currently, BNT111 is in Phase II clinical trial evaluation for the treatment of Advanced Melanoma.

• VMT01: Perspective Therapeutics
VMT01 is a theranostic radiopharmaceutical specifically designed for the treatment of unresectable or metastatic melanoma. It targets tumor sites expressing MC1R, a protein often overexpressed in metastatic melanoma tumors, to deliver 212Pb. The mechanism involves direct cell killing via high-dose radiation and promoting an immunogenic response to enhance immune-mediated tumor destruction. VMT01 has received Fast Track Designation from the FDA and is currently in Phase I/II clinical evaluation.

• IO-102-IO-103: IO Biotech
IO-102-IO-103 is a dual therapy being developed in combination with nivolumab. In clinical trials, this combination achieved rapid, deep, and durable responses, even in patients with poor prognostic factors, without increasing high-grade adverse events compared to anti-PD-1 therapy alone. The FDA has granted Breakthrough Therapy Designation for the combination. Currently, IO-102-IO-103 is in Phase III stage of its development for the treatment of Advanced Melanoma.

For more information on the Advanced Melanoma Emerging Drugs Profile, download DelveInsight's comprehensive Advanced Melanoma Pipeline Insight report @ https://www.delveinsight.com/sample-request/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Advanced Melanoma Pipeline Report Provides

• Detailed insights about companies developing therapies for Advanced Melanoma, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Advanced Melanoma treatment.
• Advanced Melanoma companies involved in targeted therapeutics development with respective active and inactive projects.
• Advanced Melanoma drugs under development based on stage, route of administration, monotherapy or combination therapy, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the Advanced Melanoma market.

Learn more about Advanced Melanoma drug opportunities in our comprehensive pipeline report @ https://www.delveinsight.com/sample-request/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Advanced Melanoma Companies and Competitive Landscape

There are 55+ key companies developing therapies for Advanced Melanoma, including Pfizer, BioNTech SE, Genmab, Hanmi Pharmaceutical, Replimune, Perspective Therapeutics, and others. Replimune is among the companies with candidates in the most advanced registration stage.

DelveInsight's Advanced Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Advanced Melanoma products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Advanced Melanoma treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Advanced Melanoma Pipeline Report

• Coverage: Global
• Advanced Melanoma Companies: Pfizer, BioNTech SE, Genmab, Hanmi Pharmaceutical, Replimune, Perspective Therapeutics, IO Biotech, and others.
• Advanced Melanoma Therapies: BNT111, VMT01, IO-102-IO-103, RP1, Belvarafenib, and other undisclosed pipeline candidates.
• Advanced Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.